In this short video, key players in the respiratory disease field in Europe look at it’s importance and how a thriving translational medicine field can help enhance the life sciences industries, public health and health life science economies. Due to the intense regulatory process that have evolved over the past few decades, this type of research is important. But often times the development life cycles and costs to bring these medications to the market are far too expensive. Barriers that hold back speedy process include low numbers of clinical trials validate these diseases and multiple protocols to conduct clinical trials in different countries.
Watch the full video here: